Why Aphios’ Bryoid composition patent matters beyond Alzheimer’s disease research
Aphios has a new Bryoid patent allowance. The bigger test is whether marine-derived PKC biology can move from IP promise to clinical proof.
Mabwell’s 9MW5211 gets FDA clearance, but can a first-in-class autoimmune antibody break through?
Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.
What TG Therapeutics, Inc.’s AAN 2026 updates reveal about real-world performance of BRIUMVI in multiple sclerosis
Explore how TG Therapeutics, Inc.’s BRIUMVI data at AAN 2026 could reshape real-world MS treatment and adoption trends. Read the full analysis now.
How Tenvie Therapeutics is testing whether neuroinflammation can become the next obesity treatment frontier
Tenvie Therapeutics begins Phase 1 dosing of TNV262. Find out why this CNS-penetrant NLRP3 inhibitor could reshape obesity and CVD treatment.
What TG Therapeutics’ ACTRIMS strategy signals about the next competitive phase in anti-CD20 multiple sclerosis therapy
Find out how TG Therapeutics’ ACTRIMS strategy reshapes competition in anti-CD20 multiple sclerosis therapy and what clinicians and regulators are watching next.
What makes LNK01006 a potentially best-in-class TYK2 inhibitor with central immune impact?
Lynk Pharmaceuticals and Formation Bio have entered an exclusive licensing and development agreement for LNK01006, a next-generation, central nervous system (CNS)-penetrant TYK2 inhibitor. The deal gives Formation Bio global rights to the asset outside Greater China, with plans to initiate a Phase 1 clinical trial in the United States during the first half of 2026. […]